Astellas
As of the edition of 20 October 2026, Astellas runs 176 drugs, 67 of them marketed; it is on route A at 27 targets and on route B at 24 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Astellas was merged in 2025.
The records place 30 company names in this family.
- LyphoMed: acquired in 1990; successor Astellas Pharma Inc.
- Yamanouchi Europe Bv: acquired in 2005; successor Astellas Pharma Inc.
- Astellas Pharma Inc.: merged in 2025
- Ophthotech Corporation: renamed
Drugs by status
| Status | Count |
|---|---|
| Marketed | 67 |
| Active | 16 |
| Went quiet | 57 |
| Stopped | 31 |
| Status not established | 5 |
| Total | 176 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Tacrolimus anhydrous | Ends 2028 (exclusivity) | 3 |
| Midazolam | none listed | 1 |
| Erlotinib | none listed | 2 |
| Celecoxib | none listed | 2 |
| Oxytocin | none listed | 1 |
| Amoxicillin | none listed | 0 |
| Sodium chloride | none listed | 0 |
| Enzalutamide | Ends 2027 (patent) | 1 |
| Quetiapine | none listed | 4 |
| Metronidazole | none listed | 0 |
| Magnesium sulfate anhydrous | none listed | 0 |
| Clarithromycin | none listed | 0 |
| Furosemide | none listed | 2 |
| Heparin | none listed | 5 |
| Clonidine | none listed | 0 |
| Mirabegron | none listed | 1 |
| Degarelix | none listed | 1 |
| Amphotericin b | none listed | 0 |
| Evolocumab | Ends 2028 (orphan exclusivity) | 2 |
| Solifenacin | none listed | 2 |
| Triamcinolone | none listed | 0 |
| Clindamycin | none listed | 0 |
| Enfortumab vedotin | Ends 2031 (computed from the first US licence) | 1 |
| Gilteritinib | Ends 2032 (patent) | 2 |
| Roxadustat | none listed | 4 |
A route B row is one company at one target. 42 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 27 targets, route B at 24 targets.
All 51 rows on route A or B
In the product51 company-target rows on route A or B; 48 are not shown here, and no score is.
See all 51 targets where Astellas needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 127 trials led
- Urinary and reproductive: 120 trials led
- Pregnancy and women's health: 101 trials led